← Every company
Regeneron Pharmaceuticals Inc Lobbying
What Regeneron Pharmaceuticals Inc discloses spending to lobby Congress, and who it pays to do it. Every lobbying firm files quarterly under the Lobbying Disclosure Act, naming its client, its fee and the issues it worked.
REGN on carbonthat →Disclosed spend
$1.8M
across every filing on file
Filings
12
Years covered
1
Firms retained
4
What it lobbies about
Health IssuesMedicare/MedicaidCopyright/Patent/TrademarkTrade (domestic/foreign)Taxation/Internal Revenue CodeBudget/Appropriations
12 filings
Newest year first, and within a year the largest fee first — a filing period is a word rather than a date, so it cannot order itself.
| Period | Lobbying for them | Disclosed |
|---|---|---|
| 20261st Quarter (Jan 1 - Mar 31) | REGENERON PHARMACEUTICALS, INCHealth IssuesMedicare/Medicaid | $640K |
| 20262nd Quarter (Apr 1 - June 30) | REGENERON PHARMACEUTICALS, INCHealth IssuesMedicare/Medicaid | $630K |
| 20262nd Quarter (Apr 1 - June 30) | CHECKMATE GOVERNMENT RELATIONSHealth Issues | $90K |
| 20261st Quarter (Jan 1 - Mar 31) | BGR GOVERNMENT AFFAIRSHealth Issues | $90K |
| 20261st Quarter (Jan 1 - Mar 31) | CHECKMATE GOVERNMENT RELATIONSHealth Issues | $90K |
| 20262nd Quarter (Apr 1 - June 30) | BGR GOVERNMENT AFFAIRSHealth Issues | $90K |
| 20261st Quarter (Jan 1 - Mar 31) | CRANE STRATEGIESBudget/Appropriations | $50K |
| 20262nd Quarter (Apr 1 - June 30) | CRANE STRATEGIESBudget/Appropriations | $50K |
| 20262nd Quarter (Apr 1 - June 30) | ARNOLD & PORTER KAYE SCHOLER LLPHealth Issues | $50K |
| 20262nd Quarter (Apr 1 - June 30) | THE WASHINGTON TAX & PUBLIC POLICY GROUPTaxation/Internal Revenue Code | $30K |
| 20261st Quarter (Jan 1 - Mar 31) | THE WASHINGTON TAX & PUBLIC POLICY GROUPTaxation/Internal Revenue Code | $30K |
| 20261st Quarter (Jan 1 - Mar 31) | ARNOLD & PORTER KAYE SCHOLER LLPBudget/AppropriationsHealth Issues | — |
A filing reports either the fee paid to a lobbying firm or what a company spent lobbying for itself, never both, so the total is a sum of the two. The client is named as filed, which is often a subsidiary. Lobbying is lawful, disclosed and extremely common — the figure is context, not an accusation.
More on REGN
Company overviewEverything on REGN in one place, with the price.SEC filingsWhat REGN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat REGN's own officers and directors buy and sell.Executive payWhat REGN awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in REGN.Funds holding itWhich funds and ETFs hold REGN, and how big a bet.Who lobbies for itThe lobbyists on REGN's account, and who they worked for.Federal contractsWhat federal agencies pay REGN.PatentsWhat REGN is filing at the patent office.